21-OHD
1 clinical trials · Condition
| Record | Firm | Date |
|---|---|---|
| A Phase 2 Study to Evaluate the Safety, Efficacy and PK of Tildacerfont in Children Aged 2-17 Years With CAH (NCT05128942) | Spruce Biosciences | 2021-12-10 |
Track 21-OHD automatically
Every clearance here is in the API, with alerts when new ones post.